Nothing Special   »   [go: up one dir, main page]

ATE397621T1 - Hemmer der interaktion zwischen p53 und mdm2 - Google Patents

Hemmer der interaktion zwischen p53 und mdm2

Info

Publication number
ATE397621T1
ATE397621T1 AT97935511T AT97935511T ATE397621T1 AT E397621 T1 ATE397621 T1 AT E397621T1 AT 97935511 T AT97935511 T AT 97935511T AT 97935511 T AT97935511 T AT 97935511T AT E397621 T1 ATE397621 T1 AT E397621T1
Authority
AT
Austria
Prior art keywords
compounds
mdm2
interaction
human
inhibitors
Prior art date
Application number
AT97935511T
Other languages
English (en)
Inventor
David Lane
Volker Boettger
Angelika Boettger
Stephen Picksley
Heinz-Kurt Hochkeppel
Carlos Garcia-Echeverria
Patrick Chene
Pascal Furet
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614197.3A external-priority patent/GB9614197D0/en
Priority claimed from GBGB9707041.1A external-priority patent/GB9707041D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE397621T1 publication Critical patent/ATE397621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplifiers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97935511T 1996-07-05 1997-07-04 Hemmer der interaktion zwischen p53 und mdm2 ATE397621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614197.3A GB9614197D0 (de) 1996-07-05 1996-07-05
GBGB9707041.1A GB9707041D0 (en) 1997-04-07 1997-04-07 Inhibitors of the interaction between p53 and mdm2

Publications (1)

Publication Number Publication Date
ATE397621T1 true ATE397621T1 (de) 2008-06-15

Family

ID=26309649

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97935511T ATE397621T1 (de) 1996-07-05 1997-07-04 Hemmer der interaktion zwischen p53 und mdm2

Country Status (8)

Country Link
EP (1) EP0958305B1 (de)
JP (1) JP2001500365A (de)
AT (1) ATE397621T1 (de)
AU (1) AU3847997A (de)
CA (1) CA2259149A1 (de)
DE (1) DE69738754D1 (de)
NZ (1) NZ333609A (de)
WO (1) WO1998001467A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
AU7238098A (en) * 1997-05-15 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (de) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Phenoxyessigsäure- und Phenoxymethyltetrazolderivate mit Antitumoraktivität
DE69922372T2 (de) * 1998-05-26 2005-12-15 Agency For Science, Technology And Research Polypeptide aus creb-binding-protein und verwandtem protein p300 für die verwendung bei der transkriptionsregulation
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040038902A1 (en) * 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
WO2004073615A2 (en) 2003-02-13 2004-09-02 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
CA2544223C (en) 2003-11-05 2017-03-07 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8598127B2 (en) * 2004-04-06 2013-12-03 Korea Research Institute Of Bioscience & Biotechnology Peptides for inhibiting MDM2 function
ES2337146T3 (es) * 2004-04-22 2010-04-21 Ortho-Mcneil Pharmaceutical, Inc. Complejos inhibidores hdm2 y usos de los mismos.
ES2558928T3 (es) 2007-01-31 2016-02-09 Dana-Farber Cancer Institute, Inc. Péptidos p53 estabilizados y usos de los mismos
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
SG176783A1 (en) * 2009-06-16 2012-01-30 Univ Tokai Anti-gram-negative bacteria agent
WO2011005219A1 (en) * 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
US20120149661A1 (en) 2009-08-26 2012-06-14 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
EP2721008B1 (de) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituierte isochinolinone als p53 (mdm2 or mdm4) inhibitoren
EP2721007B1 (de) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl-isochinolinon-verbindungen
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
AU2012334080B2 (en) * 2011-11-09 2016-12-15 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
CA2913697A1 (en) 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
EP3004112B1 (de) 2013-05-28 2017-08-30 Novartis AG Pyrazolo-pyrrolidin-4-on-derivate und ihre verwendung bei der behandlung von krankheiten
ES2656471T3 (es) 2013-05-28 2018-02-27 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
CN112245565A (zh) 2014-09-24 2021-01-22 艾瑞朗医疗公司 拟肽大环化合物及其用途
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
EP3458101B1 (de) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac-antikörper-konjugate und verfahren zur verwendung
JP2021506814A (ja) 2017-12-15 2021-02-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化ペプチドによって介在される標的タンパク質の分解
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109206474A (zh) * 2018-11-27 2019-01-15 青岛海洋生物医药研究院 一种线性肽合成方法
EP3927362A4 (de) * 2019-02-20 2022-11-23 Oncolyze, Inc. Hdm2-antikörper zur behandlung von krebs
CN112266407B (zh) * 2020-09-28 2023-05-12 宁夏医科大学总医院 特异结合p53蛋白的七肽、编码基因、制备方法及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Also Published As

Publication number Publication date
NZ333609A (en) 2000-08-25
JP2001500365A (ja) 2001-01-16
CA2259149A1 (en) 1998-01-15
WO1998001467A2 (en) 1998-01-15
AU3847997A (en) 1998-02-02
EP0958305A2 (de) 1999-11-24
DE69738754D1 (de) 2008-07-17
EP0958305B1 (de) 2008-06-04

Similar Documents

Publication Publication Date Title
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
ES2157994T3 (es) Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa.
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
MXPA02011303A (es) Nueva composicion farmaceutica.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DE60028970D1 (de) An her2 bindende peptidverbindungen
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0958305

Country of ref document: EP

REN Ceased due to non-payment of the annual fee